A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma

Muscle and Nerve

Volumn 55, Issue 6, 2017, Pages E25-E26

  Alnahhas, Iyad ^a   Wong, Jason ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; HUMAN IMMUNOGLOBULIN; PEMBROLIZUMAB; PREDNISONE; PYRIDOSTIGMINE; TRAMETINIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; HUMAN; MALE; MELANOMA; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VERY ELDERLY; COMPLICATION; CRANIAL NERVE; FATALITY; PATHOLOGY;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CRANIAL NERVES; FATAL OUTCOME; HUMANS; MALE; MELANOMA; MYASTHENIA GRAVIS;

EID: 85017188020     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.25496     Document Type: Article

References (11)

1. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210–225.
2. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–2465.
3. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52:307–308.
4. Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016;46:86–88.
5. Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2015;33:e122–124.
6. Sciacca G, Nicoletti A. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve 2016;54:504–509.
7. Antonia SJ, López-Martin JA, Bendell J. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–895.
8. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16:589–593.
9. Maeda O, Yokota K, Atsuta N. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 2016;78:119–122.
10. Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 2016;54:506–507.
11. Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 2016;54:157–161.